REG - CelLBxHealth PLC - Board changes

CellbxhealthAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260112:nRSL4265Oa&default-theme=true

RNS Number : 4265O  CelLBxHealth PLC  12 January 2026

12 January 2026

 

CelLBxHealth plc (the "Company")

 

Board changes

 

Guildford, UK and Plymouth Meeting, US - CelLBxHealth plc (AIM: CLBX), a
leader in circulating tumour cell (CTC) intelligence, with tests and services
supporting research, drug development and clinical oncology, is pleased to
announce that further to the announcement of 15 December 2025, that the
following have been appointed to the board with immediate effect:

 

·      Peter Collins as Chief Executive Officer

·      Klaas de Boer as Non-Executive Director

·      Kim Oreskovic as Non-Executive Director

·      Benjamin Hart as Non-Executive Director

 

The information required in accordance with Rule 17 and Schedule 2(g) of the
AIM Rules for Companies is detailed at the end of this announcement.

 

Separately Non-Executive Director, Joseph Eid will step down from the board,
effective 31 January 2026.

 

Jan Groen, Executive Chair of CelLBxHealth plc, said: "We welcome Peter and
the non-executives to the board.   Their extensive expertise, combined with
additional life sciences experience will significantly enhance the board's
capabilities as we focus on strategic opportunities and delivering long-term
shareholder value. We would also like to thank Joseph for his assistance over
his tenure and wish him all the best for the future."

 

For further information:

 

 CelLBxHealth plc                                               +44 (0) 1483 343434

 Peter Collins, Chief Executive Officer                         investor@CelLBxHealth.com
 Cavendish (NOMAD and Broker)

 Geoff Nash / Isaac Hooper / Hamza Munshi (Corporate Finance)   +44 (0) 20 7220 0500

 Sunila de Silva (Corporate Broking)

 Nigel Birks (Life Science Specialist Sales)
  FTI Consulting                                                +44 (0) 203 727 1000

 Simon Conway, Ciara Martin, Sam Purewal

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the EU Market Abuse
Regulation (596/2014) as it forms part of UK domestic law by virtue of the
European Union (Withdrawal) Act 2018, as amended. Upon the publication of
this announcement via a regulatory information service, this information is
considered to be in the public domain.

 

About CelLBxHealth plc

 

CelLBxHealth plc is a leading CTC intelligence company specialising in
innovative circulating tumour cell (CTC) solutions for use in research, drug
development and clinical oncology. Its patent-protected Parsortix® platform
harvests CTCs from blood and can be integrated with existing laboratory
instruments for comprehensive downstream analysis - including whole-cell
imaging, proteomic profiling and full genomic workflows.

 

Commercial activities centre on (1) Product Sales: Accelerating Parsortix
platform adoption and consumable sales through CROs and clinical lab
partnerships. (2) Laboratory services: Clinical trial support and assay
development (3) Lab Developed Tests (LDTs): Strategic partnerships combined
with a focused in-house development programme.

 

 The product portfolio comprises the Parsortix® platform with associated
consumables and assays. Laboratory services are delivered from CelLBxHealth's
GCLP certified UK laboratory, providing bespoke clinical-trial support and
assay development.

 

For more information, visit https://cellbxhealth.com/
(https://cellbxhealth.com/) .

 

AIM Rules Schedule 2 (g) information

 

The directorships and partnerships currently held by Peter Michael Collins,
aged 67, and over the five years preceding the date of this announcement are
as follows:

 

 Current directorships  Previous directorships held in the past five years
                        Saga Diagnostics UK Limited
                        SAGA Diagnostics AB

                        Collins Biotech Consulting SRL

 

The directorships and partnerships currently held by Klaas De Boer, aged 60,
and over the five years preceding the date of this announcement are as
follows:

 

 Current directorships                    Previous directorships held in the past five years
 Tsjukemar Ltd                            Entrepreneurs Fund Management LLP

 General Fusion Inc                       Entrepreneurs Fund Management Services Ltd

 Xeros Technology Group plc               veriNOS Pharmaceuticals GmbH (Previously known as vasopharm GmbH)

 SmartKem Inc                             Stichting Administratiekantoor Bellevue

 Smartkem Ltd

 Fashion for Good BV

 

 

The directorships and partnerships currently held by Benjamin Jacob Hart, aged
38, and over the five years preceding the date of this announcement are as
follows:

 

 Current directorships                    Previous directorships held in the past five years
                                          Applied Technology Partners LLC

 

The directorships and partnerships currently held by Kimberley Anne Oreskovic,
aged 60, and over the five years preceding the date of this announcement are
as follows:

 

 Current directorships                    Previous directorships held in the past five years
 Innoviance Investments B.V.
 Innoviance Consulting B.V.

 

 

There are no further disclosures required under Rule 17 and Schedule 2(g) of
the AIM Rules for Companies.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAEAXFFFAFKEFA



            Copyright 2019 Regulatory News Service, all rights reserved